dioleoyl-phosphatidylethanolamine and Psoriasis

RNA interference (RNAi) is a rapidly emerging approach for targeted gene silencing to alleviate disease pathology. However, lack of efficient carriers for targeted delivery delays the clinical translation of RNAi. An interesting target for local RNAi therapeutics is the skin as it allows direct access to target cells. Still, applications are limited due to the effective skin barrier which hinders penetration. Herein, a description is given of a liposomal carrier, called 'DDC642', capable of delivering RNAi molecules to the epidermis of impaired and intact human skin, without targeting the dermis or circulatory system. In a psoriasis tissue model, down-regulation of the psoriasis marker human beta-defensin 2 by DDC642-delivered siRNA was confirmed, providing proof-of-concept. These liposomes thus hold great potential as topical delivery system for RNAi therapeutics in the treatment of numerous skin diseases.

Topics: Administration, Topical; beta-Defensins; Cholesterol; Elasticity; Ethanol; Fatty Acids, Monounsaturated; Gene Transfer Techniques; Humans; Keratinocytes; Liposomes; Melanocytes; MicroRNAs; Phosphatidylethanolamines; Psoriasis; Quaternary Ammonium Compounds; RNA Interference; RNA, Small Interfering